# Phase I Study of Safety and Immunogenicity of ADU-623

> **NCT01967758** · PHASE1 · COMPLETED · sponsor: **Providence Health & Services** · enrollment: 11 (actual)

## Conditions studied

- Astrocytic Tumors
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Brain Tumor

## Interventions

- **BIOLOGICAL:** Cohort 1
- **BIOLOGICAL:** Cohort 2
- **BIOLOGICAL:** Cohort 3
- **DRUG:** Antibiotics

## Key facts

- **NCT ID:** NCT01967758
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-08
- **Primary completion:** 2018-06-18
- **Final completion:** 2018-08-15
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01967758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01967758, "Phase I Study of Safety and Immunogenicity of ADU-623". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01967758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*